Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis

Published:2021-11-28 Issue: Volume: Page:
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Luo Man (Melody)¹,Zhu Peijuan (Penny)¹,Nnane Ivo¹,Xiong Yuan¹,Merlini Giampaolo²,Comenzo Raymond L³,Kastritis Efstathios⁴,Wechalekar Ashutosh D.⁵,Weiss Brendan M.¹,Tran NamPhuong⁶,Qin Xiang¹,Vermeulen Jessica⁷,Sharma Amarnath¹,Sun Yu‐Nien¹,Zhou Honghui¹

Affiliation:

1. Janssen Research & Development LLC Spring House Pennsylvania USA

2. Amyloidosis Research and Treatment Center Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and Department of Molecular Medicine University of Pavia Pavia Italy

3. Division of Hematology/Oncology John C. Davis Myeloma and Amyloid Program Tufts Medical Center Boston Massachusetts USA

4. Department of Clinical Therapeutics National and Kapodistrian University of Athens School of Medicine Athens Greece

5. University College London London UK

6. Janssen Research & Development Los Angeles California USA

7. Janssen Research & Development Leiden The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1994

Reference37 articles.

1. Systemic immunoglobulin light chain amyloidosis;Merlini G;Nat Rev Dis Primers,2018

2. Guidelines on the management of AL amyloidosis;Wechalekar AD;Br J Haematol,2015

3. Light‐chain (AL) amyloidosis: diagnosis and treatment;Sanchorawala V;Clin J Am Soc Nephrol,2006

4. Clinical efficacy of high‐dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628;Dhodapkar MV;Blood,2004

5. A modified high‐dose dexamethasone regimen for primary systemic (AL) amyloidosis;Palladini G;Br J Haematol,2001

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AL amyloidosis: an overview on diagnosis, staging system, and treatment;Frontiers in Hematology;2024-05-08

2. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14

3. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab;Clinical Pharmacokinetics;2023-05-02

4. Daratumumab in AL amyloidosis;Blood;2022-12-01

5. Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration;The AAPS Journal;2022-10-20